BIOMIND LABS INC. (3XI) - Total Liabilities
Based on the latest financial reports, BIOMIND LABS INC. (3XI) has total liabilities worth €1.62 Million EUR (≈ $1.89 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BIOMIND LABS INC. - Total Liabilities Trend (2021–2024)
This chart illustrates how BIOMIND LABS INC.'s total liabilities have evolved over time, based on quarterly financial data. See 3XI working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
BIOMIND LABS INC. Competitors by Total Liabilities
The table below lists competitors of BIOMIND LABS INC. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gore Street Energy Storage Fund Plc
LSE:GSF
|
UK | GBX666.94K |
|
Axilion Smart Mobility Ltd
TA:AILN
|
Israel | ILA1.41 Million |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
Korea | ₩81.45 Billion |
|
WOODPECKER.CO ZY -10
F:8FG
|
Germany | €4.87 Million |
|
N2OFF Inc
NASDAQ:NITO
|
USA | $4.67 Million |
|
Vanquis Banking Group PLC
LSE:VANQ
|
UK | GBX3.01 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down BIOMIND LABS INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 3XI market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 28.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOMIND LABS INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOMIND LABS INC. (2021–2024)
The table below shows the annual total liabilities of BIOMIND LABS INC. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.34 Million ≈ $1.57 Million |
-10.95% |
| 2023-12-31 | €1.51 Million ≈ $1.76 Million |
+347.35% |
| 2022-12-31 | €336.72K ≈ $393.66K |
+0.53% |
| 2021-12-31 | €334.95K ≈ $391.60K |
-- |
About BIOMIND LABS INC.
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical tria… Read more